Project cooperation
A vaccine against ETEC for both children in LMIC and travellers. SBH is currently preparing for the start of pivotal phase III trial
Author
Björn Sjöstrand
CEO
Scandinavian Biopharma
Stockholm, Sweden
13 profile visits
Entrepreneur and CEO with a Passion for Global Health. SBH develops the most advanced ETEC vaccine in the world.
My organisation
We are a research-based specialty biopharma company determined to give people all over the world a longer and better life.
We are currently preparing the start of pivotal phase III trials and expect to the first vaccine preventing diarrhoea caused by ETEC in both endemic populations and travellers.
We distribute a wide range of specialty biopharma products with focus on vaccines and immunoglobulins.
About me
Entrepreneur and CEO with a Passion for Global Health
Executive with extensive experience in the life science sector, particularly in vaccines and specialty pharmaceuticals. Former CEO of SBL Vaccines under PowderJect and the Chiron Group, where I led a successful management buyout. Following the acquisition by Crucell, I served as Group Head of the fully integrated vaccine business unit (1,000 employees) and later as Chief Business Officer of Crucell.
In 2010, I founded Scandinavian Biopharma AB with a clear mission: to develop the world’s first vaccine against enterotoxigenic Escherichia coli (ETEC) for both children in low- and middle-income countries and for travellers. SBH is advancing this groundbreaking oral vaccine and is currently preparing for the start of pivotal phase III trial while also distributing specialty pharmaceuticals across Europe.